Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
69,598,317
-
Share change
-
+324,738
-
Total reported value
-
$2,575,871,087
-
Put/Call ratio
-
203%
-
Price per share
-
$37.01
-
Number of holders
-
181
-
Value change
-
+$1,537,961
-
Number of buys
-
102
-
Number of sells
-
83
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2024
As of 30 Jun 2024,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
181 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
69,598,317 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, BlackRock Inc., VANGUARD GROUP INC, Kynam Capital Management, LP, EVENTIDE ASSET MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Polar Capital Holdings Plc, Bellevue Group AG, and STATE STREET CORP.
This page lists
181
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.